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Abstract 
The main strategies for the design of telechelic polymers synthesized by reversible-activation radical 
polymerization for biomedical applications are covered spanning from drug delivery and targeting to 
theranostic and sensing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Functional polymers are of paramount importance in materials sciences to conceive macromolecular 
architectures with advanced properties.1-3 According to IUPAC, they are defined as polymers that 
bear "specified chemical groups" or polymers that have "specified physical, chemical, biological, 
pharmacological, or other uses which depend on specific chemical groups".4 It includes polymers 
with self-assembling, selective binding/coupling or catalytic abilities and affects various applications 
such as nanomedicine,5, 6 organic electronic devices,7 solar energy conversion and storage,8 or smart 
materials (e.g., self-healing polymers).9  
Among the different classes of functional polymers, end-functional polymers possess 
important benefits as their structures are crucial for the design of many industrially relevant materials 
(e.g., block copolymers, network, elastomers, macromonomers, surfactants) or strong value-added 
polymers (e.g., bioconjugates, nanoparticles, organic electronics).10 Telechelic polymers are end-
functional polymers bearing reactive end-groups at both chain-ends.11 They can be either 
homotelechelic (same functionality at both chain-ends) or heterotelechelic (different chain-ends), also 
called heterobifunctional polymers (Figure 1a). A convenient way to prepare telechelic polymers 
relies on the use of reversible-deactivation radical polymerization (RDRP), such as nitroxide-
mediated radical polymerization (NMP),12 atom-transfer radical polymerization (ATRP)13 or 
reversible addition-fragmentation chain transfer (RAFT) polymerization.14 Not only these 
polymerization techniques allow well-defined polymers to be obtained, but they also exhibit high α,ω 
chain-end fidelity enabling facile and efficient α,ω functionalization.12, 15, 16  
In the biomedical field, telechelic polymers are particularly interesting as they offer an 
opportunity to embed two different biologically active entities at the chain-ends, such as drugs, 
ligands, imaging agents or functional sites for binding or advanced properties (Figure 1b). This 
Feature Article will cover the main strategies for the design and use of telechelic polymers from 
RDRP (both organic and organic/inorganic systems) for biomedical applications, spanning from drug 
delivery to targeting, imaging/sensing and other applications. 
 
Figure 1. (a) Schematic representations of homotelechelic (left) and heterotelechelic (right) 
polymers. (b) Main biologically relevant entities currently used for the design of telechelic polymers 
from RDRP techniques for biomedical applications: drugs, proteins and oligonucleotides (drug 
delivery), fluorescent probes (tracing/imaging), gold nanoparticles/surfaces (biosensing, 
hyperthermia) and iron oxide nanoparticles (imaging, magnetic guidance). 
 
1. Organic systems 
Telechelic polymers end-functionalized with organic (macro)molecules allow a broad range of 
different polymers to be synthesized for application in drug delivery, protein bioconjugation, imaging 
and sensing.  
 
1.1 Drug delivery 
The design of drug-functionalized polymers (often termed polymer prodrug) is of crucial importance 
for drug delivery as they allow the limitations associated with traditional drug-loaded polymer 
nanocarriers (e.g., the "burst release", the difficulty to encapsulate poorly soluble drugs and the poor 
drug loadings) to be circumvented, or at least alleviated.17 The development of polymer prodrugs 
represents a relatively new research field that gained popularity in recent times, mostly in the field of 
cancer therapy.17, 18 Among the different approaches to prepare polymer prodrug nanocarriers by 
RDRP, the most popular are the "grafting to" and "grafting from" approaches that consist in 
functionalizing, with the drug of interest, preformed polymer or monomer, respectively. As for the 
emerging "grafting through" strategy (also called "drug-initiated"),19 it relies on the controlled 
growth of a short polymer chain from a drug, used as an initiator to position the drug at one of the 
polymer chain-end; generally on the α-position (Figure 2).20-24 Exploiting the presence of RDRP 
moieties at the other extremity (i.e., nitroxide for NMP, halide atom for ATRP and chain transfer 
agent for RAFT), providing the living chain fraction is high, can allow to position another molecule 
of interest for biomedical applications.  
 
 
Figure 2. “Drug-initiated” synthesis of drug-polymer conjugates by RDRP methods. The drug is 
first functionalized by a RDRP moiety (alkoxyamine for NMP or chain transfer agent for RAFT 
polymerization), followed by the controlled growth of a polymer chain to yield a drug-polymer 
prodrug that can be formulated into the corresponding drug-polymer prodrug nanoassemblies. 
Adapted with permission from ref. 19. 
 
To combine therapeutic and targeting purposes, heterobifunctional polymers have been conceived to 
display a drug and a targeting ligand. Among the different ligands available for targeting purposes,25 
antibodies are perhaps the most reliable ones as they are very specific regarding their target with high 
interaction affinities and have specific binding sites in many diseases, including cancer.26 
For instance, a heterotelechelic polyacrylamide (PAAm) bearing biotin and doxorubicin 
(Dox) at each chain-end was synthesized from a biotin-functionalized chain transfer agent (CTA) to 
perform RAFT polymerization (Figure 3).27 Dox was further linked at the ω-chain-end via thiol-
maleimide chemistry. The polymer backbone also contained pendant metal-chelating moieties (MCP) 
functionalized with diethylenetriaminepentaacetic acid (DTPA) to chelate 111In, an Auger electron 
emitting radionuclide to cause lethal DNA double strand breaks. By exploiting the strong non-
covalent bond between streptavidin (SAv) and biotin (this interaction is the strongest known non-
covalent bond with KD ~10−15 M, allowing the formation of stable complexes),28 trastuzumab Fab 
(tmFab) fragments were then covalently linked to SAv prior its linkage to the biotinylated polymer 
for the targeting of cancer cells via the HER2 receptor. Efficiency of targeting was assessed by surface 
plasmon resonance and confocal microscopy revealed the uptake of the functionalized polymer by 
SK-BR-3 breast cancer cells.  
 
 
Figure 3. Structure of heterotelechelic α-biotin, ω-doxorubicin PAAm for further binding with 
streptavidin-trastuzumab Fab fragment and targeting of cancer cells. Adapted with permission from 
ref. 27. 
 
Even though antibodies are highly specific ligands, other molecules could advantageously be used 
for targeting purposes,25 such as small peptides deriving from the RGD sequence that can specifically 
bind to an overexpressed receptor at the surface of tumour cells. They are less bulky, less fragile and 
less expensive than antibodies, and similar strategies could be developed to position RDG sequences 
to the polymer chain-end.  
Following a similar concept than for the construction of α-biotin, ω-Dox PAAm, a drug and 
a fluorescent dye were positioned at each polymer chain-end to combine therapeutic and imaging 
abilities.29 It was achieved by combining the "drug-initiated" synthesis of a α-drug polymer conjugate 
and its post-functionalization to link the fluorescent dye at the ω-extremity. In brief, paclitaxel (Ptx) 
was first conjugated to a RAFT agent and a short, well-defined poly(N,N-dimethylacrylamide) 
(PDMA) chain was subsequently grown from it. By taking benefit from the end-terminal thiol 
obtained after removal of the RAFT agent, the ω-chain-end of the polymer was subsequently 
functionalized with a rhodamine derivative through maleimide chemistry to yield Ptx-PolyDMA-Rho 
conjugates (Figure 4).  
 
Figure 4. (a) Synthesis of heterotelechelic α-Ptx, ω-rhodamine PDMA by RAFT polymerization 
from a Ptx-RAFT agent followed by a post-functionalization to link the fluorescent dye at the ω-
extremity and nanoprecipitation to yield the corresponding fluorescent polymer prodrug 
nanoparticles. (b) Synthetic strategy for the synthesis of heterotelechelic α-Ptx, ω-rhodamine PDMA. 
Adapted with permission from ref. 29. 
 
The fluorescent polymer prodrugs were formulated into nanoparticles and gave high anticancer 
activity in vitro on SKOV-3 human ovarian cancer cells, close to that of the parent drug as shown by 
MTT assays. Interestingly, they exhibited similar in vitro efficacy than Genexol-PM and Abraxane. 
On the other hand, the rhodamine moiety enabled cell internalisation experiments.  
Interestingly, Matyjaszewski and co-workers showed the preparation of telechelic di-biotin 
polymers by ATRP from a difunctional ATRP initiator.30 One can imagine to use such 
heterobifunctional polymer as intermediate block builder to link two different complexes through 
biotin/SAv binding. 
Another utility of telechelic polymers is to design high molecular weight, segmentable 
polymers for drug delivery applications, to enhanced accumulation in the tumour tissue by the 
enhanced permeability and retention effect. To this aim, homotelechelic poly[N-(2-hydroxypropyl) 
methacrylamide)] (PHPMA) chains were prepared by RAFT polymerization from a difunctional CTA 
and connected together by means of difunctional GFLG sequences via copper(I)-catalysed azide–
alkyne Huisgen cycloaddition (CuAAC),31 thiol–divinylsulfone32 or thiol–maleimide coupling 
(Figure 5).32  
 
 
Figure 5. Synthesis of multisegmented PHPMA by a combination of RAFT polymerization of HPMA 
from a α,ω-dialkyne trithiocarbonate chain transfer agent, followed by CuAAC between the resulting 
α,ω-dialkyne PHPMA and α,ω-diazide GFLG peptide sequence. Adapted with permission from ref. 
33. 
 
This approach was further extended to multi-segmented polymer prodrugs by copolymerizing HPMA 
and drug-bearing methacrylamide derivatives based on gemcitabine (Gem),34 Ptx,35 or both for 
combination therapy.36 The in vivo activity was compared to that of low molecular weight polymer 
counterparts and free drugs, showing major advantages in the use of the high molecular weight 
polymer.37 Using the same approach,  another combination involving Gem and DACH Platinum (mP-
GEM and mP-DACH Pt, respectively), was prepared and tested on A2780 human ovarian cancer 
cells. The best synergistic effect was found when mP-GEM was administered for 24 h followed by 
mP-DACH Pt for 48 h.38 
 
1.2 Imaging and sensing 
Small fluorochromes are commonly used as model molecules to prepare functionalized polymers, 
usually to prove the easiness or the efficacy of functionalization. Model heterotelechelic polymers 
bearing two different dyes can easily be prepared by ATRP39 or RAFT40 by taking benefit from 
efficient chain-end functionalization. The latter was also selected to synthesize homotelechelic 
polymer carrying pyrene41 or naphthalene.42  
Such polymers bearing two different dyes could find application in imaging/sensing such as 
FRET (Fluorescence Resonance Energy Transfer),43 bioimaging, theranostic, or simply for tracing 
purposes, for instance by confocal microscopy or other optical imaging techniques. FRET refers to 
the distant-dependant energy transfer that can occur between two different chromophores; a donor 
and an acceptor. This may be of great importance for polymer physics allowing to measure polymer 
conformation, end-to-end distance or end group interactions.44, 45  
RDRP techniques are well-suited to design materials for FRET studies because of the narrow 
dispersity of the resulting polymer (the polymer chains have nearly the same length and thus end-to-
end distances are rather similar from one chain to another) and the easy functionalization of both 
chain-ends. For instance, ATRP46 was employed to synthesize α,ω-dye-functionalized polymers 
bearing anthryl and carbazolyl groups (Figure 6). They were prepared from anthryl-functionalized 
ATRP initiators followed by substitution of the bromine group by an azide moiety and subsequent 
CuAAC with carbazolyl alkyne.  
 
 
Figure 6. Synthetic routes for α,ω-dye-functionalized PS and PMMA bearing anthryl and carbazolyl 
groups as FRET pairs. Anthryl moieties are first derivatized with ATRP initiating groups for the 
subsequent ATRP of styrene or methyl methacrylate, followed by chain end azidation and CuAAC 
with carbazolyl-alkyne. Adapted with permission from ref. 46. 
 
A similar approach was reported on Oregon Green Cadaverin and Texas red as FRET pairs for the 
conception of α,ω-dye-functionalized polymers.47 Diethylene glycol methacrylate (DEGMA) was 
polymerized by RAFT from a pentafluorophenyl (PFP) activated ester RAFT agent followed by: (i) 
amination of PFP with Oregon Green Cadaverin to the α position and (ii) aminolysis of the RAFT 
end group by excess of n-propylamine in the presence of Texas Red-2-sulfonamidoethyl 
methanethiosulfonate to create a disulfide bond connecting the dye (Figure 7). Assuming Förster-
type process, an average end-to-end distance of 4.5 nm was calculated, in reasonable agreement with 
data obtained from light scattering. 
 
 
Figure 7. RAFT synthesis of PDEGMA (1) from pentafluorophenyl activated ester RAFT followed 
by successive attachment of Oregon Green Cadaverin (2) by amidation on the α position (3) and 
Texas Red-2-sulfonamidoethyl methanethiosulfonate (4) by disulfide bond formation after 
aminolysis of the RAFT end group (5). Adapted with permission from ref. 47. 
 
1.3 Peptide/protein conjugation 
Therapeutic proteins are used for a broad range of pathologies with different purposes, such as 
increasing the amount of lacking natural proteins, upregulating existing metabolic pathways, 
inhibiting molecules or organisms or as targeting agents in tumour therapy.48 Unfortunately, some 
limitations are still present: proteins are rapidly cleared from the circulating system by the 
reticuloendothelial system or metabolized by peptidases or proteases leading to a loss of biological 
activity.  
The construction of polymer-protein bioconjugates can help overpass these problems. The 
well-known "PEGylation" technique, that consists in the attachment of a poly(ethylene glycol) (PEG) 
chain to a protein/peptide, brings several advantages: it increases bioavailability and plasma half-
lives, it enhances biocompatibility and decreases immunogenicity, reduces proteolysis and enhances 
solubility and stability.49, 50 In the past few decades, RDRP techniques offered the possibility to use 
more complex and tailor-made polymers with advanced properties to synthesize polymer-
protein/peptide bioconjugates.51-53 
The introduction of a second biological moiety at the other extremity of a polymer-
protein/peptide bioconjugate can be of great interest to confer additional beneficial properties. 
Aminoacids or small peptides are commonly used as model molecules, leading to interesting proofs 
of concept. For instance, an heterotelechelic α-aldehyde, ω-thiol polyvinylpyrrolidone (PVP) 
synthesized by RAFT polymerization was functionalized with glycine-D,L-serine and phenyl acrylate, 
respectively.54 Also, by starting from difunctional trithiocarbonate RAFT agents bearing aminooxy 
groups or pyridyl disulfide (PDS) groups (Figure 8a and b), corresponding homotelechelic 
poly[oligo(ethylene glycol) methyl ether acrylate] (POEGA) polymers were successfully prepared 
(Figure 8c and d). They were then post-functionalized at both chain-ends with either glutathione 
(GSH) or benzyl mercaptan.55  
 
 
Figure 8. Structure of difunctional, symmetric (a) N-Boc-aminooxy trithiocarbonate, (b) pyridyl 
disulfide trithiocarbonate, (c) telechelic N-Boc-aminooxy POEGA and (d) telechelic pyridyl disulfide 
POEGA. Adapted with permission from ref. 55. 
 
Synthesis of a telechelic thiol-reactive polymer and its subsequent conjugation to N-acetyl-L-cysteine 
methyl ester as a thiol-containing model molecule was also reported.56 ATRP of styrene was initiated 
from a protected maleimide ATRP initiator followed by atom-transfer radical coupling to yield the 
corresponding homotelechelic polymer. The amino acid was then linked through maleimide 
chemistry to both chain-ends (Figure 9). Noteworthy is the fact that this strategy could be easily 
applied to other polymers and thiol-containing biomolecules that would be relevant for biomedical 
applications. 
 
 
Figure 9. Synthesis of telechelic thiol-reactive polymer by ARTP and subsequent atom-transfer 
radical coupling, followed by conjugation to N-acetyl-L-cysteine methyl ester. Adapted with 
permission from ref. 56. 
 
Bovine serum albumin (BSA) and lysozyme are commonly used as model proteins because of the 
easiness of covalent linkages offered by the presence of a free cysteine residue (Cys34) or several 
lysine residues, respectively. Different approaches were employed to synthesize heterotelechelic 
polymers bearing BSA on one chain-end (via thiol/maleimide linkage) and another biomolecule at 
the other extremity. For instance, an alkyne-biotin was clicked through CuAAC to RAFT-constructed 
α-azide, ω-PDS heterobifunctional poly(N-isopropylacrylamide) (PNIPAAm) before subsequent 
coupling to BSA to form a disulfide linkage and to avidin (Av) via its binding to the biotinylated end 
group.57 Similarly, BSA and SAv were linked to a heterobifunctional α-biotin, ω-maleimide 
PNIPAAm made by RAFT, through its maleimide and biotin end groups, respectively (Figure 10).58  
 
 
Figure 10. Synthesis of heterotelechetic polymer-protein bioconjugates by RAFT polymerization of 
NIPAAm from a biotinylated chain transfer agent, followed by end-functionalization with a 
maleimide group and subsequent coupling with BSA via thioether bond formation and SAv via 
binding with biotin. Adapted with permission from ref. 53. 
 
In another study, heterobifunctional polymers bearing BSA on one side and another molecule on the 
other were prepared.59 A BSA macro-RAFT agent bearing a PDS group was prepared from the 
reaction between BSA and a PDS-difunctionalized CTA, leaving one PDS group intact because of 
steric hindrance. It was followed by RAFT polymerization of OEGA or HPMA leading to BSA-
POEGA and BSA-PHPMA bioconjugates in situ. Then thiol-functionalized rhodamine B and 
thiocholesterol were linked through PDS linkage to form the corresponding heterobifunctional 
polymers.  
Strategies to position the same protein at both chain-end were also reported. For instance, 
linear homotelechelic PNIPAAm bearing on α and ω position a mutant V131C T4 lysozyme (T4L), 
that contains one free cysteine, was successfully prepared either via maleimide linkage  (Figure 11a)60 
or via a new tetrazine linker (Figure 11b) which improved coupling yields.61 The synthetic route was 
based on a bis-carboxylic acid RAFT agent that was reacted, after polymerization, with either a furan-
protected maleimide alcohol or (4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)methanol to install at both 
chain-ends maleimide or tetrazine moieties, respectively (Figure 11c). This approach was further 
extended to four-armed star-PNIPAAm with T4L at each polymer end.62  
 
Figure 11. Structure of homotelechelic PNIPAAm bearing (a) maleimide or (b) tetrazine moieties. 
(c) and homodimerization of T4L with homotelechelic PNIPAAm bearing either maleimide or 
tetrazine functional groups. Adapted with permission from ref. 61. 
 
More sophistication can be implemented by conferring reversible linkages in the structure of dual-
functionalized bioconjugates. A heterotelechelic α-biotin, ω-maleimide PNIPAAm containing a 
cleavable disulfide bond between biotin and the polymer was synthesized by RAFT polymerization 
and used to reversibly modify surfaces with proteins.63 T4L was linked to the maleimide group and 
the conjugate was anchored to a Av-coated surface through biotin/Av linkage. The conjugate was 
released from the surfaces under mild reducing conditions demonstrating the reversibility (Figure 12). 
 
 
Figure 12. (a) Structure of heterotelechelic α-biotin, ω-maleimide PNIPAAm containing a cleavable 
disulfide bond between the biotin and the polymer, after conjugation of BSA via thiol/maleimide 
linkage. (b) Immobilization of the conjugate via the biotin-SAv interaction and release from the 
surface by reduction of the disulfide bound. Adapted with permission from ref. 63. 
 
Other non-covalent interactions than biotin/SAv (or biotin/avidin (Av) or biotin/neutravidin (NAv)) 
have been reported for the design of biorelated telechelic polymers. For instance, Theato and co-
workers built on their previous study47 where a pentafluorophenyl (PFP) activated ester RAFT agent 
was used to prepare heterotelechelic polymers bearing two different dyes, to report a heterotelechelic 
biofunctionalized polymer via hormone thyroxine-prealbumin linkage (Figure 13).64 A PFP-
poly[di(ethylene glycol) methyl ether methacrylate] (PFP-PDEGMA) was reacted with the hormone 
thyroxine (T4) followed by end-capping with biotinylated methane thiosulfonate during aminolysis 
of the RAFT end group. T4 and biotin end groups specifically bounded to prealbumin and SAv, 
respectively. Subsequent immobilization onto a self-assembled monolayer of T4-disulfide surface 
was performed with the polymer connecting the two different proteins with its end groups.  
 
 
Figure 13. Synthesis of α-hormone thyroxine (T4), ω-S-S-biotin PDEGMA and subsequent binding 
with prealbumin and SAv, respectively, followed by surface immobilization. Adapted with 
permission from ref. 64. 
 
The non-covalent interaction between GSH and glutathione-S-transferase (GST) was also employed 
for the synthesis of heterotelechelic polymers.65 Synthesis of heterotelechelic α-GSH, ω-biotin 
PNIPAAm was performed by RAFT, followed by coupling with GST and SAv in solution. α-GSH, 
ω-biotin PNIPAAm was further shown to separately bind GST-tagged Rac1, a potential cancer 
marker, and biotin-tagged BSA. 
 
1.4 Oligonucleotide bioconjugation 
Even though not many examples of dual-functionalization are present in the literature, nucleic acid 
(e.g., DNA, RNA, or small interfering RNA (siRNA)) are another class of macromolecules that gain 
great benefit from their conjugation to synthetic polymers, helping to resolve issues such as serum 
stability, low blood circulation time and lack of targeting.66  
A convenient strategy to bind them at a polymer chain-end is to react a thiol-terminated 
nucleotide with a PDS end group.67 For instance, a PDS end-functionalized polymer-dendritic 
carbohydrate scaffold was obtained by RAFT polymerization of HPMA from a RAFT agent bearing 
2-mercaptothiazolidine active ester function. The resulting polymer was further reacted with 
dendritic-mannose G2Man on the ω-end group, followed by aminolysis to install PDS group on the 
α position. Conjugation to a short interfering RNA then led to the heterobifunctional conjugate 
(Figure 14). This PDS end-functionalized PHPMA-dendritic carbohydrate scaffold is believed to be 
a versatile precursor for bioconjugations, as the synthetic procedure can easily accommodate a range 
of sugar functionalities. 
 
 
Figure 14. Synthesis of heterobifunctional siRNA-PHPMA-dendritic mannose biohybrid conjugates 
by RAFT polymerization of HPMA from a chain transfer agent bearing a 2-mercaptothiazolidine 
active ester group followed by coupling with dendritic-mannose G2Man on the ω chain-end and with 
a short, thiolated interfering RNA on the α position via disulphide bond formation after reaction with 
a PDS moiety. Adapted with permission from ref. 67. 
 
2. Organic/inorganic hybrid systems 
The synthesis of organic/inorganic hybrid systems can give access to materials with interesting 
features because of the nature and unique properties of inorganic entities (e.g., optical, electronic, 
physical). The use of RDRP techniques enables the synthesis of a broad range of well-defined 
functional polymers that can be attached to inorganic materials including particles, flat surfaces or 
rods. In this area, the design of telechelic polymers is of crucial importance as it allows to incorporate 
other biorelevant (macro)molecules for advanced applications. Below are reported representative 
strategies for the synthesis of organic/inorganic hybrid systems based on preformed telechelic 
polymers. Given the field of surface modification is extremely broad and rich, especially from 
surface-initiated RDRP strategies, the readers interested in this field are referred to the following 
comprehensive reviews.68-70 
 
2.1 Gold  
Gold nanoparticles (AuNPs) are subject of an incredible amount of work because of their magnetic, 
optic and electrical properties. It explains why they are widely investigated in bionanotechnology and 
biomedicine, among many other fields, especially as biosensor material.71-73 Moreover, given their 
biocompatibility and stability, AuNPs can be used as nanocarrier for nucleic acids or drugs for 
instance.74-76 Grafting a polymer at the surface of AuNPs comes with great advantages: (i) it ensures 
the colloidal stabilization of the system and can improve biocompatibility; (ii) it can tune the size of 
the particles, which plays a significant role in the modulation of optical, electric and magnetic 
properties and (iii) it opens the door to further conjugation with biorelevant entities. 
Given the most common functionalization strategy involves thiol chemistry, this makes RAFT 
polymerization the technique of choice to link RDRP polymers at the surface of AuNPs.77-81 It is 
explained by the easy reduction of the Z group of the RAFT agent to disclose a thiol end group which 
display high affinity for gold surface. Reduction can also be carried out in situ during AuNP 
formation. This approach has naturally been extended to gold surfaces82, 83 or gold nanorods 
(AuNRs),84, 85 in a rather straightforward manner.  
Gibson and co-workers reported on poly(hydroxyethyl acrylamide) (HEA),86 PVP87 and 
POEGA87 synthesised by RAFT and further grafted at the surface of AuNPs via the ω-thiol function 
after removal of the CTA’s Z group. By taking advantage of the carboxylic acid from the CTA’s R 
group, 2-deoxy-2-amino glucose (GlcNH2) or 2-deoxy-2-amino-galactose (GalNH2) were coupled to 
the α-terminus of the polymer to generate glycosylated nanoparticles AuNPs. No significant binding 
to ovine red blood cells, nor haemolysis was noticed, suggesting they are compatible with blood. This 
work is intended to guide the development of new nanoparticles for drug delivery, imaging or 
biosensing, with enhanced specificity, affinity, and stability. 
Interestingly, heterotelechelic α-amino, ω-thiol PNIPAAm prepared by RAFT polymerization 
was used as "polymeric glue" to interlink two types of gold building blocks: AuNPs and AuNRs, via 
a two-step ligand exchange approach. It created a satellite-like structure that shows unique thermo-
responsive optical properties (Figure 15).84 Given these unique properties, this nanomaterial assembly 
could be of interest in the field of biomedicine and biosensing. 
 
 
 
 
Figure 15. (a) Linkage of heterotelechelic α-amino, ω-thiol PNIPAAm at the surface of AuNRs and 
further immobilization of AuNPs. (b) Transmission electron microscopy of AuNP@AuNR assembly. 
Adapted with permission from ref. 84. 
 
Heterotelechelic polymers are naturally of great interest to immobilize proteins at the surface of gold 
nanoparticles for potential applications in drug delivery or biosensing. For instance, NIPAAm was 
polymerized by RAFT from 2-dodecylsulfanylthiocarbonylsulfanyl-2-methyl propionic acid (DMP) 
as a RAFT agent.88 After aminolysis to recover ω-thiol end groups and conjugation of biotin to the 
α-carboxylic acid group, a α-biotin, ω-thiol PNIPAAm was obtained. Its anchoring at the surface of 
AuNPs enabled their homogeneous coating and further surface functionalization with avidin 
mediated by biotin/Av binding. Similarly, Narain and co-workers immobilized heterotelechelic α-
biotin, ω-thiol glycopolymers and PNIPAAm at the surface of AuNPs.79, 80 Their incubation with Av 
showed the accessibility of the biotin ligands for conjugation and the Av-conjugated 
glyconanoparticles were found to selectively immobilize lectins. 
Flat gold surfaces are also of major interest for several biorelevant applications, such as 
biosensing, chip-based bioassays, or cell adhesion studies.89-91 Many different biorelevant molecules 
can be grafted by means of telechelic polymers used as bridge between them and the molecule to be 
linked. For instance, a RAFT-synthetized aminooxy end-functionalized PNIPAAm either served for 
the direct conjugation to BSA or was immobilized on a gold surface after reduction of the 
trithiocarbonate end-group (Figure 16).82 The resulting PNIPPAm surface was then incubated with 
an aldehyde-modified heparin to yield the polysaccharide-functionalized surface. This technique 
could be applied to the stabilization and storage of growth factors on surfaces or used to coat medical 
devices where the anticoagulant activity of heparin is needed such as for renal dialysis instruments.  
 
 
Figure 16. Structure of α-aminooxy end-functionalized PNIPAAm prepared by RAFT used either 
for the synthesis of BSA-based bioconjugates or for the grafting to flat gold surfaces via ω-thiol 
function, followed by heparin attachment via the α-aminooxy end group. Adapted with permission 
from ref. 82. 
 
In the context of biosensing and bioimaging applications, Theato, Stenzel and co-workers reported 
on a general approach towards difunctionalized RAFT polymers bearing a fluorescent dye on the α-
position and an anchoring group (S-S-CH3) on the ω-position, for the surface decoration of AuNPs 
or quantum dots (QDs).92  For AuNPs, FRET caused a fluorescence quenching of the dye, while QDs 
led to fluorescence enhancement by FRET from the QD to the tethered dyes (Figure 17). This 
synthetic route, and especially the use of a RDRP technique, allows to prepare hybrid materials with 
a tuneable distance between the inorganic species and the dyes. 
 
 
Figure 17. Au nanoparticle or QD decoration by a heterotelechelic α-dye, ω-methyl disulfide 
poly(methyl methacrylate) and effect of the nearby Au core (fluorescence quenching) or QD 
(fluorescence enhancement) on the emission of the dye. Adapted with permission from ref. 92. 
 
An additional benefit of RGD-based sequences lies on the fact that they correspond to the minimal 
adhesive domain of fibronectin and therefore allow control over cell adhesion.93 To finely tune cell 
adhesion, a targeted GGRGDS-functionalized PNIPAAm was grafted on gold surface after reduction 
of ω-trithiocarbonate moiety. When mouse fibroblasts (L929), which are adhesive cells,83 were 
cultured on the surface, a faster adhesion on functionalized surface was observed compared to that of 
unmodified PNIPAAm coating.  
 
 
2.2 Iron oxide  
Beyond small fluorochromes and QDs, other imaging agents can be used. Iron oxide nanoparticles 
(IONPs) are involved in a broad range of applications, such as immunoassay, detoxification of 
biological fluids, drug delivery, tissue repair and as contrast agents for magnetic resonance imaging 
(MRI).94-96 Surface functionalization of IONPs can be easily performed from functional polymers 
embedding suitable binding motifs.  
For example, a heterotelechelic α-phosphonic acid, ω-dithiopyridine POEGA obtained by 
RAFT was grafted to IONPs via its α-phosphonic acid moiety, allowing for IONP stabilization in 
different media (e.g., water, PBS).97 The resulting POEGA-stabilized IONPs were then successfully 
functionalized with two different peptides after modification of the ω-trithiocarbonate into 
ethylpyridyl disulfide end-group: reduced glutathione as a model peptide and NGR motif as a tumour 
targeting peptide (Figure 18).  
 
 
Figure 18. Grafting of heterotelechelic α-phosphonic acid, ω-dithiopyridine POEGA onto IONPs and 
further surface coupling via ω-dithiopyridine end group with glutathione as model peptide or the 
NGR motif for targeting purposes. Adapted with permission from ref. 97. 
 
 
Conclusion 
The aim of this Feature Article was to cover the recent achievements in the design of telechelic 
polymers by RDRP techniques for biomedical applications. In light of this survey, it appears that 
these well-defined functional materials present unique features that could be of great value in many 
several key bio-related areas including drug delivery, targeting and imaging/sensing. Enabling 
molecular weight control and precise positioning of biologically active moieties at both polymer 
chain-ends gave access to valuable tools or building blocks that could serve in tomorrow’s biomedical 
applications.  
The different examples also shed light on the robustness and a kind of supremacy of the RAFT 
technique over other RDRP methods to achieve telechelic structures for biomedical applications, 
owing to facile chain-end functionalization via removal of the RAFT agent, the broad applicability 
of thiol chemistry for bioconjugation and easy access to a broad range of functional RAFT agents.  
One could however regret the too few examples in the field of drug delivery from small 
molecules, whereas telechelic polymer-proteins/peptides have been extensively investigated. To 
achieve such a goal, the "drug-initiated" method appears key as it inherently lead to conjugates with 
one drug molecule linked at the α-position. Efficient ω-chain-end modification by drugs, biologically 
active ligands or imaging agents should result in a broad range of heterotelechelic polymer prodrugs 
that could find use in combinatorial therapy, targeted drug delivery or theranostic. 
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